Harden Kelly A, Cowan Patricia A, Velasquez-Mieyer Pedro, Patton Susan B
Family Care, PC, Dyersburg, Tennessee, USA.
J Am Acad Nurse Pract. 2007 Jul;19(7):368-77. doi: 10.1111/j.1745-7599.2007.00236.x.
The purposes of this study are threefold: to determine what components of the metabolic syndrome are present in obese adolescents, to determine what differences exist in the effects of lifestyle intervention versus lifestyle intervention plus metformin on weight management and select markers of metabolic syndrome in obese adolescents, and to determine which factors predict weight loss in obese adolescents treated with lifestyle changes and metformin.
The study was a secondary data analysis utilizing a retrospective chart review of 63 obese adolescents aged 11 through 18 who were treated for obesity at the LeBonheur Youth Lifestyle Clinic from January 1, 2000, through June 30, 2005. Lifestyle interventions included diet, exercise, and counseling. The medication utilized was metformin. Outcomes evaluated included body mass index, relative body mass index (RBMI), weight, waist and hip circumference, blood pressure, serum lipid levels, fasting plasma glucose, 2-h oral glucose tolerance tests, and insulin levels. Changes in mean values between groups were evaluated using the General Linear Models procedure. Logistic regression was utilized to determine which factors might predict weight loss.
The metformin group (N= 37) tended to be heavier, older, and had more components of the metabolic syndrome than the nonmetformin group (N= 26). All components of the metabolic syndrome were present in both groups (overall prevalence 55%). Both groups had a downward trend in RBMI, a surrogate marker for weight loss, but only the metformin group had a significant loss in RBMI points from baseline to end. There was a trend toward better diastolic blood pressure at 6 months in the metformin group (p= 0.06), which was not seen in the nonmetformin group. The only predictors of weight loss were higher RBMI (those who were heavier lost more) and the absence of type 2 diabetes mellitus (type 2 DM) (those with type 2 DM were less likely to lose 10 or more points in RBMI).
All components of the metabolic syndrome are present in obese adolescents. The use of lifestyle changes and lifestyle changes plus metformin both produce some degree of weight loss, but subjects on metformin in this study lost significantly more RBMI points than those on lifestyle changes alone. Subjects with type 2 DM are less likely to lose weight than those without type 2 DM. Larger studies and studies with subjects more representative of the general population need to be carried out to assist in the development of evidence-based practice guidelines.
本研究有三个目的:确定肥胖青少年中存在代谢综合征的哪些成分;确定生活方式干预与生活方式干预加二甲双胍在肥胖青少年体重管理及代谢综合征某些指标方面的效果有何差异;确定哪些因素可预测接受生活方式改变和二甲双胍治疗的肥胖青少年的体重减轻情况。
该研究是一项二次数据分析,利用回顾性病历审查,研究对象为2000年1月1日至2005年6月30日期间在勒邦赫青少年生活方式诊所接受肥胖治疗的63名11至18岁肥胖青少年。生活方式干预包括饮食、运动和咨询。使用的药物是二甲双胍。评估的结果包括体重指数、相对体重指数(RBMI)、体重、腰围和臀围、血压、血脂水平、空腹血糖、口服葡萄糖耐量试验2小时结果以及胰岛素水平。使用一般线性模型程序评估组间平均值的变化。采用逻辑回归确定哪些因素可能预测体重减轻。
二甲双胍组(N = 37)往往比非二甲双胍组(N = 26)更重、年龄更大,且代谢综合征的成分更多。两组均存在代谢综合征的所有成分(总体患病率55%)。两组的RBMI(体重减轻的替代指标)均呈下降趋势,但只有二甲双胍组从基线到结束时RBMI得分有显著下降。二甲双胍组在6个月时舒张压有改善趋势(p = 0.06),非二甲双胍组未观察到这种情况。体重减轻的唯一预测因素是较高的RBMI(体重较重者减重更多)以及无2型糖尿病(2型糖尿病患者RBMI降低10分或更多分的可能性较小)。
肥胖青少年中存在代谢综合征的所有成分。生活方式改变以及生活方式改变加二甲双胍均能产生一定程度的体重减轻,但本研究中使用二甲双胍的受试者RBMI得分的下降幅度明显大于仅进行生活方式改变的受试者。2型糖尿病患者比非2型糖尿病患者减重的可能性更小。需要开展更大规模的研究以及针对更具总体人群代表性受试者的研究,以协助制定循证实践指南。